ARCA biopharma is focused on developing genetically targeted therapies for cardiovascular diseases. Gencaro (bucindolol hydrochloride), the company’s lead product candidate, is an investigational, pharmacologically unique beta-blocker and mild vasodilator that is being developed for atrial fibrillation. The company has identified common genetic variations that it believes can predict individual patient response to Gencaro, which gives it the potential to be the first genetically targeted atrial fibrillation prevention treatment. For more information, visit the company’s Web site at www.arcabiopharma.com.